Reishi for Cancer Adjunct Therapy
Verdict: Published with Warning
Across 3 PubMed studies, the evidence for Reishi in Cancer Adjunct Therapy grades Tier C — weak evidence. Effective, but with safety or population caveats.
C 🟠 C Weak Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.55
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
75%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.553
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative)，由 raw_score 決定
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (3)L2 · primary research & systematic reviews
Ganoderma lucidum (Reishi mushroom) for cancer treatment
Finding: G. lucidum + chemo/radiotherapy more likely to respond positively vs chemo/radiotherapy alone (RR 1.50; 95% CI 0.90-2.51; P=0.02); immune markers improved; minimal adverse effects.
View on PubMed Coriolus Versicolor and Ganoderma Lucidum Related Natural Products as an Adjunct Therapy for Cancers: A Systematic Review and Meta-Analysis of RCTs
Finding: Pooled lower mortality (HR 0.82; 95% CI 0.72-0.94; P=0.005); higher total efficacy for G. lucidum alone (RR 1.31; P=0.004); no relapse-free survival benefit (HR 1.19; P=0.2).
View on PubMed Synergy of de-walled Ganoderma lucidum spore powder on targeted therapy in advanced EGFR-mutant non-squamous NSCLC: protocol for an RCT
Finding: Protocol only (ChiCTR2300072786); no outcome data reported yet.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
FDA has no questions source↗
L4b EU EFSA
Not addressed
1,548 claims on 'botanicals' have been placed on hold by the Commission pending further consideration on how to proceed with these source↗
L4d TW TFDA / 衛福部
Supportive
靈芝、樟芝等真菌類屬「可供食品使用」之原料；衛福部食藥署於104年3月16日公布「真菌類食品標示管理原則」（104年7月1日施行），規定外包裝須明確標示真菌類原料之中文名稱及拉丁學名，並加註其使用部位為子實體、菌絲體或子實體加菌絲體及其培養方式。靈芝為國內實施健康食品法以來第一個被認可具保肝（護肝）效果之健康食品（雙鶴極品靈芝，衛署健食字第A00003號，核可日期2000/07/24），保健功效相關成分為靈芝多醣體、靈芝三萜類，核可保健功效為免疫調節功能、護肝功能。 source↗
L5a NIH Office of Dietary Supplements
Cautious
There are no studies of G. lucidum with measured cancer outcomes. source↗
L5b Mayo Clinic
Cautious
scientists have studied reishi, but it's only been in the context of cancer treatment ... some evidence that patients treated with Ganoderma lucidum medications, combined with chemotherapy or radiotherapy, were more likely to respond compared with chemotherapy or radiotherapy alone source↗
L5e Specialty Society (condition-mapped)
Cautious
Some types of complementary methods, such as dietary supplements, have generally not been proven to help prevent or treat cancer or its symptoms, and might sometimes even cause harm. source↗